Full-Time
Updated on 8/21/2026
Develops biopharmaceutical therapies for serious diseases
$216.1k - $360.2k/yr
Sleepy Hollow, NY, USA
Hybrid
On-site in Sleepy Hollow, NY four days per week.
Bachelor's, MBA, PharmD, PhD
See people who can refer or advise you
Regeneron Pharmaceuticals develops and commercializes medicines for serious diseases, with a focus on cancer, eye diseases, allergic and inflammatory diseases, and infectious diseases. Its products come from using proprietary research capabilities and technologies to discover and develop therapies, often in collaboration with academic, research, and industry partners. Revenue comes from selling approved medicines and from licensing its technologies and entering co-development and co-commercialization partnerships. The company works with healthcare providers and regulators to ensure treatment delivery and safety. Its goal is to improve patient outcomes by bringing life-transforming medicines to market through rigorous R&D and strategic collaborations, maintaining leadership in biopharmaceutical innovation.
Company Size
10,001+
Company Stage
IPO
Headquarters
Town of Mount Pleasant, New York
Founded
1988
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Wellness Program
Paid Vacation
Equity Awards
Annual Bonuses
Flexible Work Hours
The US Food and Drug Administration has approved Regeneron's Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). FOP is an ultra-rare genetic disorder affecting approximately 900 people worldwide, where rogue bone formation infiltrates muscles, tendons and connective tissues, leading to severe disability. The approval follows results from the Phase 3 OPTIMA trial involving 63 participants. At 56 weeks, Pasatru demonstrated a 90% or greater reduction in new HO lesions compared to placebo, assessed by CT scan. The 10 mg/kg dose showed an 88% reduction in clinician-assessed flare-ups. Pasatru is a fully human monoclonal antibody that blocks Activin A, a protein critical in developing HO lesions. Regeneron's regulatory submission is under review by the European Medicines Agency.
Infinimmune raises $75m with big pharma backing for atopic dermatitis drugs. Infinimmune is targeting first-in-human studies with its longer-lasting monoclonal antibodies in 2027. Infinimmune has raised $75m in Series A financing, helping the biotech advance its atopic dermatitis (AD)-centric pipeline. As part of the round, Infinimmune garnered the interest of several major industry players, including Regeneron's venture, which co-led the biotech's raise with Playground Global, while MSD's (Merck & Co) global health innovation fund participated alongside other life sciences investors. Infinimmune already has a clear area in which it will spend the Series A tranche. While not disclosing how it will split the money, the biotech said the financing will accelerate clinical development of its two lead programmes in AD, as well as supporting additional programmes and advancing its Anthrobody discovery platform. Infinimmune's platform helps create longer-lasting antibodies while maintaining potency. It does this by screening millions of single memory B cells across hundreds of targets to identify natively paired, fully human antibodies. So far, the company has IFX-101 and IFX-201, monoclonal antibodies that target IL-22 and IL-13, respectively. First-in-human studies with the assets are slated to begin in 2027. Wyatt McDonnell, co-founder and CEO of Infinimmune, said: "The human immune system makes extraordinary antibodies. We built a company to find them and are uniquely positioned to turn them into transformative medicines for patients with unmet needs. This financing enables Infinimmune to bring that promise to the clinic, as we work alongside a world-class syndicate to develop the molecules that patients living with inflammatory diseases deserve." For Regeneron, contributing to Infinimmune's development means it is advancing a potential rival to Dupixent (dupilumab), the blockbuster anti-inflammatory injection that has dominated the AD landscape for years. Dupixent, co-marketed with Sanofi, targets both IL-4 and IL-13, meaning there is some overlap with Infinimmune's pathway targets. The patents for Dupixent, which generated $17.8bn in sales in 2025, are set to expire around 2031. Regeneron and Sanofi are already building out their pipelines to preserve their dominance in the AD market, though assets like those being developed by Infinimmune could provide future bolt-on options. Infinimmune is targeting a crowded yet lucrative market. GlobalData forecasts that AD across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) will be worth $22.4bn in 2033. GlobalData is the parent company of Pharmaceutical Technology. MSD, meanwhile, is already familiar with Infinimmune. In March 2026, Infinimmune signed a multi-target antibody discovery collaboration with the big pharma company that includes up to approximately $838m in upfront and potential milestone payments.
Biocon announces commercial launch of Yesafili in USA. 7 August 2026 India's Biocon (BSE: 5325) has announced the commercial launch of Yesafili (aflibercept-jbvf) in the USA. Yesafili, a vascular endothelial growth factor (VEGF) inhibitor used to treat various types of ophthalmology conditions, is a biosimilar of its reference product Eylea (aflibercept) 2-mg, originated by US biotech Regeneron (Nasdaq: REGN) and licensed to Germany's Bayer (BAYN: DE). The product was approved previously and granted interchangeable designation by the US Food and Drug Administration (FDA) in May 2024, allowing substitution at the pharmacy level in accordance with state laws. However, Biogen only reached an agreement with Regeneron to launch the biosimilar in the second half of 2026. This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 21 May 2024 24 October 2024 17 April 2025 Companies featured in this story. Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 7 August 2026 Company spotlight. A San Carlos, California-based immunology biotech using nanobody-based multispecific biologics to target the IL-31 itch pathway, positioning its lead asset against the Dupixent franchise in atopic dermatitis and chronic pruritus. More features in biosimilars. 5 August 2026 31 July 2026 23 July 2026 22 July 2026
Regeneron Pharmaceuticals, Inc. investors with substantial losses have opportunity to Lead Regeneron Class Action lawsuit - Hagens Berman. SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) - Hagens Berman Sobol Shapiro LLP alerts investors in Regeneron Pharmaceuticals (NASDAQ: REGN) that a securities class action lawsuit has been filed after its surprising revelations concerning a Phase 3 clinical trial of a therapy intended to treat patients with melanoma. The news that the trial failed drove the price of Regeneron shares sharply lower and, along with the severe market reaction ($11 billion market cap wipeout), triggered the lawsuit which seeks to represent investors who purchased or otherwise acquired shares of Regeneron common stock between August 1, 2025 and May 15, 2026. National shareholder rights firm Hagens Berman is investigating the legal claims and urges Regeneron investors with substantial losses to submit your losses now. The firm also invites persons who may be able to assist in the investigation to contact its attorneys. Class Period: Aug. 1, 2025 - May 15, 2026 Lead Plaintiff Deadline: Sept. 14, 2026 Visit: http://www.hbsslaw.com/investor-fraud/regn Contact the Firm Now: [email protected] 844-916-0895 Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action: The litigation is focused on the propriety of Regeneron's repeated optimism about the state of- (and changes to-) its Phase 3 trial of Fianlimab in combination with Libtayo as a first-line treatment for metastatic or locally advanced melanoma (the "Study"). The Study's primary endpoint was progression-free survival ("PFS") and Regeneron has characterized the combination as a "potential blockbuster." "Events" - disease progression or death - determined the timing and statistical power of the primary PFS analysis. The complaint alleges that Regeneron made false and misleading statements while failing to disclose critical information to investors. In particular, the lawsuit accuses the company and its management of not informing investors that the Study's preliminary statistical assumptions were flawed, the active treatment arm was not achieving meaningful differentiation over standard therapies, and achievement of its primary endpoint was unlikely. Throughout the Class Period, Regeneron and the other defendants assured investors of their confidence in the Trial's achieving its primary endpoint even when events were slowing down. At one point, management said the slowing event rates are "because the test arms are performing well." The truth began to emerge on April 29, 2026, when Regeneron first revealed that it decided to alter the Trial protocol such that "t]he primary analysis of progression-free survival will now consider all patients enrolled in the study with a minimum follow-up of 6 months." One prominent analyst reportedly questioned whether the decision was made because, in contrast to management's expressed confidence, the "underlying PFS benefit may be insufficient to show statistical significance." Then, on May 12, 2026, Regeneron admitted that the decision to alter the Trial protocol was made in response to "slow event rates," occurred nearly six months ago, and was "submitted it to all the global regulatory authorities in November, December timeframe." Three days later, the final blow came. On May 15, 2026, Regeneron abruptly reported the "trial did not reach statistical significance of the primary endpoint of improvement in progression-free survival (PFS)." "We're focused on whether Regeneron altered the Trial protocol without timely telling investors to intentionally mislead them because the defendants knew so-called blockbuster potential for the combination wasn't really there," said Reed Kathrein, the Hagens Berman partner leading the firm's investigation of the pending claims in the suit. If you invested in Regeneron and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now" If you'd like more information and answers to other frequently asked questions about the Regeneron case and the firm's investigation, read more" Whistleblowers: Persons with non-public information regarding Regeneron should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected]. About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. Attorney Advertising. Prior results do not guarantee a similar outcome in any future case. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Today in Business do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Bronstein, Gewirtz & Grossman LLC urges Regeneron Pharmaceuticals, Inc. investors to act: Class Action filed alleging investor harm. * 4 hrs ago NEW YORK, Aug. 02, 2026 (GLOBE NEWSWIRE) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between August 1, 2025 and May 15, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/REGN. Regeneron Case Details The Complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: * the preliminary statistical assumptions underlying Regeneron's Phase III Fianlimab-Libtayo study were fundamentally flawed; * the study's active treatment arm was not demonstrating meaningful clinical differentiation from standard therapies; * the study was unlikely to achieve statistical significance with respect to its primary endpoint, even absent overperformance by the control arm; and * as a result, the Company's statements regarding the study's design, progress, and prospects were materially false and/or misleading at all relevant times. What's Next for Regeneron Investors? A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/REGN. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Regeneron you have until September 14, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. No Cost to Regeneron Investors Mycarrollcountynews, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means Mycarrollcountynews will ask the court to reimburse Mycarrollcountynews for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if Mycarrollcountynews is successful. Why Bronstein, Gewirtz & Grossman, LLC for Regeneron Securities Class Action? Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Its firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com "Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC. Contact Info Peretz Bronstein, Esq. or Nathan Miller Bronstein, Gewirtz & Grossman, LLC Attorney advertising. Prior results do not guarantee similar outcomes.